UNICREDIT BANK/CALL/ELI LILLY & CO/1100/0.1/17.12.25 | Real-time BOERSE MUENCHEN 09:42:09 2024-06-27 EDT | ||
| 8.58 EUR | +0.12% |
|
| Current month | +42.36% | ||
| 1 month | +43.07% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 8.58 | +0.12% |
| 24-06-26 | 8.57 | -1.49% |
| 24-06-25 | 8.7 | +2.47% |
| 24-06-24 | 8.49 | +5.33% |
| 24-06-21 | 8.06 | +4.40% |
Real-time BOERSE MUENCHEN
Last update June 27, 2024 at 09:42 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD1UT0 |
| ISIN | DE000HD1UT06 |
| Date issued | 2024-01-15 |
| Strike | 1,100 $ |
| Maturity | 2025-12-17 (538 Days) |
| Parity | 10 : 1 |
| Emission price | 2.93 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.7 € |
|---|---|
| Lowest since issue | 2.31 € |
| Spread | 0.24 € |
| Spread % | 2.71% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
901.3
USD
Average target price
860.5
USD
Spread / Average Target
-4.52%
- Stock Market
- Warrants
- Warrant
